Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Eli lilli Thursday declare Gains that evaluate income and assessments in the first quarter Lose weight and diabetes Recently, a cancer treatment increased the management of full annual earnings due to charges related to the treatment agreement.
The pharmaceutical giant is now evaluated from $ 22.50 per share from $ 22.50 to $ 22.50 to $ 22.28 to $ 2025 and $ 22.28. Eli Lilly, first of all, is primarily due to the purchase of a certain amount of $ 1.57 billion contract in the first quarter, primarily a specific oral cancer drug.
The company maintained $ 58 billion for $ 58 billion in finance. Eli Lilly, the leadership does not include the tariffs of the President Donald Trump, which existed the existing tariffs, but in the pharmaceutical brought to the United States
In an interview with CNBC Eli Lilly CEO Dave Ricks said the company and other pharmacies have already announced Investments in US productionOne of the targeted goals of Trump management tariffs.
“I think that in fact, the threat of tariffs returns to important areas, chips and Pharma,” Ricks said. “So, should we apply (tariffs?) I’m not sure.”
He added that Eli Lilly wants to see regular low tax rates in the United States, especially for 15% local production. Ricks, a lot of less taxes to produce a pharmacy manufacturer to produce “Irish Singapore and Low Tax Islands in Switzerland” and it can return if an economic incentive. “
Eli Lilly’s Blockbuster Diabetes Treatment Mounjaro, exceeded expectations in the first quarter, to increase the expectations of $ 3.84 billion. This is a large 113% of the same period a year ago.
The company’s weight loss medication also evaluates $ 2.31 billion in sales orders in the quarter. A year ago, 517.4 million dollars of treatment were $ 517.4 million in the United States before entering the US market.
Analysts expect to sell $ 3.81 billion and $ 2.28 billion in sales, respectively $ 3.28 billion in sales.
The company’s shares in Premarket trade decreased by 5%.
According to LSEG, what Wall Street’s first quarter expects the first quarter with the first quarter of the Analytical Analysts, this is what Eli Lilly said:
- Earnings on a share: $ 3.02 expected to $ 3.34 $ 3.34
- Income: $ 12.73 billion is expected to $ 12.73 billion
The company increased by 45% of the same period from $ 12.73 billion in revenue in the first quarter.
Sales in the United States have dropped from 49% to $ 8.49 billion. Eli Lilly said that the number of 57% in volume or the number of recipes or sections sold or sections sold or zepbound and Mounjaro have been increased. According to the company, this is partially replaced by drugs decreased prices, he said.
The pharmaceutical giant ordered a net income of $ 2.76 billion per share for the first quarter or $ 3.06 per share. It is compared to the net income of $ 2.24 billion or $ 2.48 a year ago.
Except for the only one-time items associated with the cost of intangible assets and other adjustments, Eli Lilly earned $ 3.34 per quarter.
In the United States, the demand for the last year, Zepbound and Mounjaro still preferred the supply. Both so-called growth treatment imitate certain intestinal hormones to lower the appetite of a person and adjust blood sugar.
The popularity of these injectable drugs has forced both Eli Lilly and his opponent Novo Nordisk to invest in billions to increase production capacity for treatment.
It seems that the work of the work: Food and Drug Department in December reaffirmed his decision again Announcing the deficiency of the US pipzepatide – an active ingredient in Zepbound and Mounjaro. This decision effectively bar Compounding pharmacies Marketing and selling the cheaper, unspecified versions of Tirzepatid.
This story is developing. Please check again for updates.
